Alkem Laboratories Ltd. (ALKEM) 52 Week Low Streak: second straight session near yearly low

Alkem Laboratories Ltd. 52 Week Low Streak has now extended to a second straight session, with the stock trading within 2% of its 52-week low across the streak and the cumulative move down 2.24%. The latest trough seen in the streak was Rs 5,115, while the stock was last trading at Rs 5,119. The supplied data confirms the repeated-low pattern, but it does not establish a company-specific cause for the continued weakness.

At 9:23 AM IST, Alkem Laboratories Ltd. was trading below its previous close of Rs 5,146 after opening at Rs 5,199.35 and touching the same level as the day high before moving to Rs 5,115 at the day low. The market capitalisation stood at Rs 62,609.02 crore. For a reader tracking the Alkem Laboratories Ltd. 52 Week Low Streak, the key point is not a single-day move alone, but the persistence of the weak pattern across consecutive sessions.

Alkem Laboratories Ltd. 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 5,119
Previous Close	Rs 5,146
Today's Move	Rs -27 (-0.52%)
Open	Rs 5,199.35
High	Rs 5,199.35
Low	Rs 5,115
Market Capitalisation	Rs 62,609.02 crore

Alkem Laboratories Ltd. (ALKEM) traded at Rs 5,119 versus the previous close of Rs 5,146, a fall of 0.52%. The stock opened at Rs 5,199.35, reached a high of Rs 5,199.35, touched a low of Rs 5,115.

Alkem Laboratories Ltd. Share Price Today remained under pressure as the stock was last trading at Rs 5,119, down Rs 27 or 0.52% from the previous close of Rs 5,146. The intraday range so far has been narrow but firm on the downside, with the stock opening at Rs 5,199.35, touching a high of Rs 5,199.35 and slipping to a low of Rs 5,115. That places the Alkem Laboratories Ltd. Share Price Today very close to the lower end of the day’s range and near the 52-week trough identified in the streak.

The market capitalisation was Rs 62,609.02 crore, which keeps the company firmly in the large listed space even as the Alkem Laboratories Ltd. Share Price Today continues to reflect repeated weakness. The first session of this pattern started on 30 September 2026, and the second straight session confirms that the stock is still trading near its yearly low rather than staging any meaningful rebound. For investors following Alkem Laboratories Ltd. Stock News, the repeated proximity to the 52-week low is the main signal to watch, not just the small daily move.

What the Repeated 52-Week Lows Show

Alkem Laboratories Ltd. 52 Week Low Streak is important because it shows persistence rather than a one-off dip. The stock has stayed within 2% of its 52-week low for a second straight session, and the cumulative decline across that span is 2.24%. That means the weakness has carried over instead of fading after the first breakdown. Alkem Laboratories Ltd. New One Year Low is not being claimed here; the data only confirms that the share has been trading close to its 52-week trough across consecutive sessions.

From a market-reading standpoint, the pattern tells readers that the Alkem Laboratories Ltd. 52 Week Low Streak is still developing. The supplied figures confirm the streak, the current trough and the move across the two sessions, but they do not identify a company-specific trigger. In practical terms, the repeated low is a factual sign of continued pressure, and the next watchpoint is whether the stock keeps trading near this band or moves away from it. That is why searches such as Alkem Laboratories Ltd. Back To Back 52 Week Lows and Stocks At One Year Low Today fit this event closely.

Alkem Laboratories Ltd. (ALKEM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 62,609.02 crore
P/E Ratio	28.52x
P/B Ratio	4.3x
ROE	18.29%
ROCE	21.28%
EPS	Rs 180.45
Book Value Per Share	Rs 1,196.51
Dividend Yield	1.03%

Alkem Laboratories Ltd. (ALKEM) fundamental metrics show P/E 28.52x, P/B 4.3x, ROE 18.29%, ROCE 21.28%. These figures provide context only and are not a buy or sell signal.

Alkem Laboratories Ltd. has a market capitalisation of Rs 62609.02 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 28.52x, P/B at 4.3x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.29% and ROCE of 21.28%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 180.45, book value per share of Rs 1196.51, dividend yield of 1.03%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 27.95x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	28.52x
Benchmark Median P/E	27.95x
Benchmark Average P/E	41.83x
Benchmark P/E Range	0x to 688.17x
Company P/B Ratio	4.3x
Benchmark Median P/B	2.84x
Company ROE	18.29%
Benchmark Median ROE	11.7%
Company ROCE	21.28%
Benchmark Median ROCE	13.46%
Company Market Capitalisation	Rs 62,609.02 crore
Benchmark Median Market Cap	Rs 765.11 crore

Alkem Laboratories Ltd. (ALKEM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Alkem Laboratories Ltd. (ALKEM) has a P/E ratio of 28.52x, which is above the benchmark median of 27.95x, a difference of +2.04%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Alkem Laboratories Ltd. (ALKEM) has a ROE of 18.29%, which is above the benchmark median of 11.7%, a difference of +56.32%. Alkem Laboratories Ltd. (ALKEM) has a ROCE of 21.28%, which is above the benchmark median of 13.46%, a difference of +58.1%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Biocon Ltd.	BIOCON	61,602.44	122.07	1.78	1.35	3.26
Glenmark Pharmaceuticals Ltd.	GLENMARK	67,592.81	36.26	5.95	14.1	20.35
Abbott India Ltd.	ABBOTINDIA	57,939.73	35.73	11.15	34.67	46.72
Gland Pharma Ltd.	GLAND	49,315.14	42.45	4.51	10.56	14.96
Ipca Laboratories Ltd.	IPCALAB	49,280.78	37.33	5.76	15.88	19.41

Alkem Laboratories Ltd. (ALKEM) has a P/E ratio of 28.52x compared with the displayed peer median of 37.33x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.29% compares with a peer median of 14.1% across the companies shown in the table. ROCE stood at 21.28% versus the displayed peer median of 19.41%, providing a capital-efficiency comparison. Alkem Laboratories Ltd. (ALKEM) has a market capitalisation of Rs 62,609.02 crore. Among the 5 peers shown, 1 have a larger market capitalisation.

Why Investors Are Watching

• Alkem Laboratories Ltd. 52 Week Low Streak has now run for a second straight session, which keeps the share near its yearly low.
• The cumulative move across the streak is down 2.24%, making the pattern more than a one-session dip.
• The supplied data confirms the repeated-low pattern but does not establish a company-specific cause for the weakness.
• Valuation metrics and return ratios remain important because the company is still generating healthy ROE and ROCE relative to the industry.
• Peers in the healthcare and pharma space show a wide spread in valuation, so Alkem Laboratories Ltd. Share Price needs to be read in sector context.

About the Company

Alkem Laboratories Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company is tracked on NSE and BSE and remains one of the more established healthcare names by market capitalisation. In the supplied figures, the business shows a market value of Rs 62,609.02 crore, supported by earnings per share of Rs 180.45 and book value of Rs 1,196.51.

The current numbers also show a P/E of 28.52, P/B of 4.3, ROE of 18.29% and ROCE of 21.28%. Those metrics matter because they help place the Alkem Laboratories Ltd. 52 Week Low Streak in a broader company context rather than treating the price move as a standalone event. The article data does not provide an ownership snapshot, so the analysis here remains centred on price, valuation and industry comparison.

Frequently Asked Questions

What does Alkem Laboratories Ltd. 52 Week Low Streak mean?

Ans. It means Alkem Laboratories Ltd. has traded within 2% of its 52-week low for a second straight session. The pattern shows repeated weakness near the yearly low, but it does not by itself explain why the stock is under pressure.

Has Alkem Laboratories Ltd. hit a new 52-week low today?

Ans. The supplied data confirms that the stock traded near its 52-week low, with an intraday low of Rs 5,115. It does not say that a new 52-week low was definitively set today.

What was Alkem Laboratories Ltd. trading at in the latest update?

Ans. At the reported time, Alkem Laboratories Ltd. was last trading at Rs 5,119, compared with the previous close of Rs 5,146. The stock remained close to the lower end of the day’s range.

Is Alkem Laboratories Ltd. expensive on valuation?

Ans. Its P/E of 28.52 and P/B of 4.3 sit near to slightly above industry medians in the supplied healthcare data. That does not make it extreme, but it also does not suggest a deep valuation discount.

How do Alkem Laboratories Ltd. ROE and ROCE compare with the sector?

Ans. Alkem Laboratories Ltd. has ROE of 18.29% and ROCE of 21.28%, both above the supplied industry medians. That indicates relatively strong return metrics even while the share price remains weak.

How does Alkem Laboratories Ltd. compare with pharma peers?

Ans. Compared with peers like Lupin, Glenmark, Abbott India and Biocon, Alkem sits in the middle on valuation and profitability. Its peer comparison shows a balanced but not clearly cheap profile.

What should investors monitor next in Alkem Laboratories Ltd. Stock News?

Ans. Investors should watch whether the share keeps trading near the 52-week low or moves away from it. The key point is the repeated pattern itself, since the supplied data confirms weakness but not a specific trigger.

Track Alkem Laboratories Ltd. (ALKEM) Share Price on Univest

Use Alkem Laboratories Ltd. (ALKEM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.